Last updated: February 9, 2024
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
Overall Status: Active - Recruiting
Phase
N/A
Condition
Osteoarthritis
Treatment
Triamcinolone Hexacetonide and hyaluronic acid
Triamcinolone Hexacetonide
Clinical Study ID
NCT05408065
2023-10659
Ages > 20 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- A clinical examination that confirms the radiological diagnosis of moderate to severeprimary shoulder osteoarthritis, stage II and above, according to the Samilson-Prietoclassification.
- Patients aged between 20 and 90 years.
- A patient with bilateral shoulder osteoarthritis will choose the side of theinfiltration, only one side can be chosen to participate in the study.
- The patient must have a clinical pain threshold of a minimum of 4/10 on the visualanalogue scale.
- The patient must have the cognitive ability to read and fill out the questionnaires.
- The patient must be able to read and understand French or English
Exclusion
Exclusion Criteria:
- Presence of a transfixing rotator cuff tear assessed on MRI.
- No previous shoulder reconstruction surgery.
- Pregnant woman.
- A patient who has received a cortisone infiltration within 6 months prior to the startof the study.
- A patient who has received a platelet-rich plasma or a hyaluronic acid infiltrationwithin 12 months prior to the start of the study.
- Diagnosis of avascular necrosis.
- Disease affecting the studied joint (systemic inflammatory disease, history of septicarthritis, osteonecrosis, etc.)
- Suspicion or presence of active local infectious process.
- Presence or suspicion of neoplasia or local metastasis.
- Severe trauma to the shoulder ( ≤ 3 months)
- Significant cognitive impairment or insufficient language proficiency to adequatelyanswer the questionnaires.
- Any other serious medical condition that does not allow participation in the study ormay be a contraindication to cortisone injection.
Study Design
Total Participants: 84
Treatment Group(s): 2
Primary Treatment: Triamcinolone Hexacetonide and hyaluronic acid
Phase:
Study Start date:
November 15, 2022
Estimated Completion Date:
December 31, 2026
Study Description
Connect with a study center
Centre Hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec H2X 0C1
CanadaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.